June 19, 2024: Fred Hutch Science Spotlight covers out work on implantable scaffolds for the in-situ programming of CAR T-cells
Read the full story here:
https://www.fredhutch.org/en/news/spotlight/2024/06/tst-inamdar-jctrlrelease.html
June 3, 2024: Fred Hutchinson Cancer Center is highlighting our gene therapy foam research
Read the full story here:
https://www.fredhutch.org/en/news/center-news/2024/06/stephan-gene-therapy-foam.html
May 29, 2024: Our group introduces foam as a new delivery vehicle for gene therapy drugs.
December 7, 2023: Sanofi highlights the In Vivo Cell Reprogramming technology developed by the Stephan laboratory at their 2023 R&D Day.
October 4, 2023: Nature interviews Prof. Stephan about the future of mRNA medicines.
March 30, 2022: The Controlled Release Society (https://www.controlledreleasesociety.org) has chosen our 2021 JCR paper, entitled: “Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity” as “Best Paper in 2021”.
https://www.sciencedirect.com/science/article/pii/S0168365921004466?via%3Dihub
The award sponsored by Elsevier is given to the lead author of an outstanding original paper published in Journal of Controlled Release related specifically to the field of delivery and bioactives (not an invited, a review, or from a special meeting). The article will have been published the previous year in the Journal of Controlled Release.
September 2 2021. Fred Hutchinson Cancer Research Center highlights our efforts to translate nanotechnologies into clinical therapies
https://www.fredhutch.org/en/news/center-news/2021/09/Fred-Hutch-business-development.html
January 14 2021. Congratulations to Fan for starting his independent research group at the University of Florida Health (https://zhang.pharmacy.ufl.edu).
July 23 2020. Thank you, GeekWire and the Seattle community for voting the T cell delivering thin film implant our team developed “Health Innovation of the Year”!
June 25 2020. Genetic Engineering & Biotechnology News highlights our nanoparticle CAR-T gene delivery research.
https://www.genengnews.com/insights/nonviral-genetic-engineering-of-car-t-cells
February 11, 2020. The Stephan Laboratory has been selected as a finalist in the “Health Innovation of the Year” category for the upcoming GeekWire Awards taking place March 26 at the Museum of Pop Culture in Seattle. The committee recognizes the T-cell delivery device our group developed, that was recently licensed by MonarchBio for further development with the goal to maximize the success of tumor surgery, and to spare patients from repetitive operations, extended hospital stays, and rounds of radiation or chemotherapy.
https://www.geekwire.com/2019/thin-metal-films-loaded-immune-cells-show-promise-cancer-fighting-therapy
Other finalists in this category, chosen after a month-long nomination and judging process include: Athira Pharma, Blaze Bioscience, Sana Biotechnology, and Sound Life Sciences. To cast your vote, click here:
February 16, 2020. Dr. Stephan was invited to join other leaders in cancer cell and gene therapy at the ACGT CANCER SUMMIT 2020 to showcase and discuss the most innovative cancer research programs.
February 14, 2019. The Nanotechnology Characterization Laboratory accepts the Stephan lab into their program to facilitate the clinical translation of targeted mRNA nanocarriers for the treatment of ovarian cancer.
December 04, 2018. The Alliance for Cancer Gene Therapy (ACGT) selects Prof. Stephan as 2018 Innovator Grant Recipient.
November 21, 2018. “The Heart of the Hutch” video campaign launches with members of the Stephan lab.
October 30, 2018. Prof. Stephan named Allen Distinguished Investigator
https://www.geekwire.com/2018/allen-frontiers-group-awards-13-5m-research-cancer-cells-aging-brains/
https://www.eurekalert.org/pub_releases/2018-10/ai-tpg102518.php
https://centernet.fredhutch.org/cn/n/2018/10/matthias-stephan-allen-distinguished-investigator.html
July 2, 2018. Fred Hutchinson Cancer Research Center highlights our recent publication in Cancer Research
June 12, 2018. Dr. Fan Zhang, a postdoctoral fellow in our laboratory, was awarded a $100,000 postdoctoral fellowship by The American Brain Tumor Association to develop nanoparticles that can be used to reprogram tumor-infiltrating macrophages.
December 21, 2017. Nature Outlook covers our work on in situ-programming of tumor-specific T cells.
https://www.nature.com/magazine-assets/d41586-017-08701-8/d41586-017-08701-8.pdf
August 30, 2017 Media coverage of our work to simplify CAR T-cell manufacturing using synthetic mRNA nanocarriers
http://www.sciencecodex.com/nanoparticles-loaded-mrna-give-disease-fighting-properties-cells-613988
https://medicalxpress.com/news/2017-08-nanoparticles-mrna-disease-fighting-properties-cells.html
https://www.drugtargetreview.com/news/25223/nanoparticles-disease-cells/
https://scienmag.com/nanoparticles-loaded-with-mrna-give-disease-fighting-properties-to-cells/
http://www.nanowerk.com/nanotechnology-news/newsid=47883.php
April 1, 2017. The Scientist Magazine® is highlighting our work in the field of implantable T-cell delivery devices in their April issue.
November 29, 2016. Geekwire, a national technology news site and radio show (geekwire.com) highlights the biopolymer implants developed by the Stephan group. Listen to the podcasts here:
September 21, 2016. Fred Hutchinson Cancer Research Center features our work in immunobioengineering in the Fall 2016 Fall Advertising Campaign.
The ad will run in the following publications
-Washington DC Business Journal: 9/30
-USA Today- Future of Cancer Care Insert: 9/23
-Sunset Magazine- October Issue
-Wired and The New Yorker- November Issue
-Alaska Airlines magazine- December Issue
April 1, 2016. Prof. Stephan has been named the recipient of a 2016 Research Scholar Grant from the American Cancer Society. The Stephan lab will use this 4-year grant to develop injectable reagents that can quickly reprogram the patient’s immune cells (particularly T lymphocytes) to recognize and destroy tumors.
May 22, 2015. The Stephan lab’s research is highlighted on the Fred Hutchinson Cancer Research Center’s webpage: “The right tools for the job: taking immunotherapy to the next level”.
http://www.fredhutch.org/en/news/center-news/2015/05/taking-immunotherapy-to-next-level.html
January 23, 2015. Prof. Stephan receives the National Science Foundation CAREER Award.
.
November 20, 2014. The Stephan lab's first paper, entitled “Biopolymer implants enhance the efficacy of adoptive T cell therapy”, was accepted for publication by Nature Biotechnology.
April 2, 2014. Nature and Nature Biotechnology have invited the Stephan lab to present their work at the 2014 Biotechnology International Organization (BIO) Convention in San Diego. The conference is entitled “Genomic Technologies and Biomaterials for Understanding Disease” and will be held at the San Diego Convention Center on June 23 and 24, 2014.
March 12, 2014. Dr. Stephan was elected to serve as Associate Scientific Advisors for Science’s sister journal, Science Translational Medicine.
http://stm.sciencemag.org/site/about/assoc_advisors.xhtml
Science Translational Medicine invited members of the Advisory Board and principal investigators from Clinical and Translational Science Awards (CTSA) recipient institutions to nominate outstanding early-career translational scientists to serve as Associate Scientific Advisors for the journal. From this collection of nominees, the journal editors selected 26 Associate Advisors. With this program, Science Translational Medicine seeks to build connections with the community of trainees in translational medicine. In addition to acting as research advisors for Science Translational Medicine, these scientists will scan selected journals and choose and summarize research papers to be highlighted in the Editors' Choice section. Each Associate Advisor will have 8 to 10 of their articles appear in Science Translational Medicine over the next year.
November 7, 2013. The Stephan lab was invited to present their work on biomaterial-supported T-cell implants at the Nature Scicafe event in San Francisco. This exclusive scientific forum that operates on an invitation-only basis and is hosted by the editors of Nature Biotechnology and Nature Medicine. This event provides the participating scientists with new connections and insight from the business audience regarding the potential commercialization of their work.